Q4 Revenue Consensus at $18.29M
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 08 2026
0mins
Q4 revenue consensus $18.29M.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like ADCT with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on ADCT
Wall Street analysts forecast ADCT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ADCT is 7.33 USD with a low forecast of 5.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 3.540
Low
5.00
Averages
7.33
High
10.00
Current: 3.540
Low
5.00
Averages
7.33
High
10.00
About ADCT
ADC Therapeutics SA is a Switzerland-based clinical-stage oncology drug discovery and development company. It develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. It employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The Company has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. It serves customers in the United States, Switzerland, and the United Kingdom.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ADC Therapeutics Faces Securities Fraud Investigation, Stock Drops 14.13%
- Investigation Launched: Pomerantz LLP is investigating whether ADC Therapeutics has engaged in securities fraud or other unlawful business practices, which could undermine investor confidence and lead to stock volatility.
- Clinical Trial Data: On December 3, 2025, ADC released data from the LOTIS-7 trial indicating that 36.7% of patients experienced cytokine release syndrome; despite positive framing, the occurrence of adverse events could tarnish the company's reputation.
- Stock Price Reaction: Following the clinical data release, ADC's stock price fell by $0.65, a 14.13% drop, closing at $3.95 per share, reflecting market concerns about the company's future prospects.
- Legal Context: Pomerantz LLP, a prominent securities class action firm with over 85 years of experience, is dedicated to protecting investor rights, and adverse findings from the investigation could result in significant financial liabilities for the company.
Continue Reading
ADC Therapeutics Faces Securities Fraud Investigation as Stock Drops 14.13%
- Investigation Launched: Pomerantz LLP is investigating ADC Therapeutics for potential securities fraud, which could undermine investor confidence and lead to further stock price volatility.
- Clinical Trial Data Update: On December 3, 2025, ADC released data from the LOTIS-7 trial indicating that 36.7% of patients experienced cytokine release syndrome, and while the data was presented positively, the associated risks may affect market acceptance of its products.
- Stock Price Reaction: Following the release of adverse clinical data, ADC's stock price fell by $0.65, or 14.13%, closing at $3.95 per share on December 3, 2025, reflecting market concerns about the company's future prospects.
- Legal Implications: Pomerantz LLP, a prominent securities class action firm, may initiate legal proceedings against ADC, potentially impacting shareholder interests and the company's reputation.
Continue Reading